Audience: Population health decision-makers

Client: Johnson & Johnson

Goal: Educate PHDMs on unmet need in the non-small cell lung cancer space and market the value of a new combination drug indication for non-small cell lung cancer with epidermal growth factor mutations (EGFR)

Role: Researched, wrote, and led client and regulatory reviews ahead of FDA approval and launch